Antibody Information

General Information of This Antibody
Antibody ID
ANI0VZIZQ
Antibody Name
IMGN-388
Synonyms
IMGN-388 mAb
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG
Antigen Name
Integrin alpha-V (ITGAV)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
IMGN-388 [Terminated in phase 1]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Advanced solid tumors.
Administration Dosage
Doses ranging from 5 to 80 mg/m2, every 3 weeks, IV.
Related Clinical Trial
NCT Number NCT00721669  Clinical Status Phase 1
Clinical Description
A phase 1 dose-escalation study of IMGN388 in patients with solid tumors.
Primary Endpoint
No evidence of activity was observed at the lowest doses (45 mg/m2) evaluated.
Other Endpoint
No evidence of human anti-human antibody formation (data available for doses up to 60 mg/m2.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT00721669  Clinical Status Phase 1
Clinical Description
A phase 1 dose-escalation study of IMGN388 in patients with solid tumors.
Primary Endpoint
Five patients (breast,prostate,neuroendocrine,and 2 NSCLC) treated at doses 45 mg/m2 have acheived stable disease for 4 cycles.
References
Ref 1 A phase I dose-escalation study of IMGN388 in patients with solid tumors. Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010) 3058-3058.
Ref 2 A phase I study of IMGN388, an antibody drug conjugate targeting av integrin, in patients with solid tumors.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.